TABLE 5.
Correlations between BDNF promoter IV methylation and clinical measures in HD patients.
| Age | CAG | MMSE | MOTOR | TFC | HADS | |
| Site 444 | ||||||
| Pearson r | –0.1823 | 0.2772 | –0.2358 | –0.1612 | 0.1574 | –0.5179 |
| 95% confidence interval | −0.5693to0.2708 | −0.1756to0.6332 | −0.6059to0.2182 | −0.5544to0.2908 | −0.2944to0.5517 | −0.7761to−0.1109 |
| P value (two-tailed) | 0.4289 | 0.2239 | 0.3034 | 0.4852 | 0.4955 | 0.0162 |
| P value summary | ns | ns | ns | ns | ns | ∗ |
| Site 445 | ||||||
| Pearson r | –0.1862 | 0.141 | –0.1579 | –0.179 | 0.1387 | –0.533 |
| 95% confidence interval | −0.5720to0.2670 | −0.3096to0.5399 | −0.5520to0.2939 | −0.5670to0.2739 | −0.3117to0.5383 | −0.7843to−0.1315 |
| P value (two-tailed) | 0.419 | 0.5421 | 0.4942 | 0.4374 | 0.5487 | 0.0128 |
| P value summary | ns | ns | ns | ns | ns | ∗ |
| Site 446 | ||||||
| Pearson r | –0.09932 | 0.2046 | –0.2974 | –0.1395 | 0.1238 | –0.5048 |
| 95% confidence interval | −0.5093to0.3474 | −0.2492to0.5847 | −0.6462to0.1542 | −0.5388to0.3110 | −0.3253to0.5274 | −0.7690to−0.09335 |
| P value (two-tailed) | 0.6684 | 0.3737 | 0.1905 | 0.5465 | 0.5928 | 0.0196 |
| P value summary | ns | ns | ns | ns | ns | ∗ |
| Site 437 | ||||||
| Pearson r | –0.2749 | 0.1826 | –0.07029 | –0.2762 | 0.1962 | 0.2656 |
| 95% confidence interval | −0.6317to0.1780 | −0.2705to0.5695 | −0.4873to0.3728 | −0.6325to0.1766 | −0.2574to0.5789 | −0.2006to0.6337 |
| P value (two-tailed) | 0.2279 | 0.4283 | 0.7621 | 0.2255 | 0.394 | 0.2578 |
| P value summary | ns | ns | ns | ns | ns | ns |
MMSE, Mini-Mental State Examination; the Unified Huntington’s Disease Rating Scale Motor component (Motor); TFC, Total Functional Capacity; p-values shown are corrected for multiple comparisons. ∗p < 0.05.